Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Cenix BioScience GmbH.


Cenix BioScience bioscience /bio·sci·ence/ (-si´ens) the study of biology wherein all the applicable sciences (physics, chemistry, etc.) are applied.

bi·o·sci·ence
n.
See life science.
 is a specialist in advanced, cell-based applications of RNA interference RNA interference
n.
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes.
 (RNAi), a breakthrough gene silencing technology for the discovery and functional characterization A rather long and fancy word for analyzing a system or process and measuring its "characteristics." For example, a Web characterization would yield the number of current sites on the Web, types of sites, annual growth, etc.  of novel therapeutic targets and drug candidates.

With over 5 years of experience focused on combining genome-driven, high throughput RNAi with high content phenotypic phe·no·type  
n.
1.
a. The observable physical or biochemical characteristics of an organism, as determined by both genetic makeup and environmental influences.

b.
 analyses in cultured human and rodent rodent, member of the mammalian order Rodentia, characterized by front teeth adapted for gnawing and cheek teeth adapted for chewing. The Rodentia is by far the largest mammalian order; nearly half of all mammal species are rodents.  cells, we offer these capabilities through fully-customizable Premium Research Services to industry and academic clients.

Our mission is to accelerate and improve the quality of therapeutic drug discovery and development in a broad range of disease areas.
Company:                Cenix BioScience GmbH

   Headquarters Address:   Tatzberg 47
                           Dresden, Saxony 01307
                           Germany

   Main Telephone:         +49 (0) 351 41730

   Website:                www.cenix-bioscience.com

   Type of Organization:   Private

   Industry:               Health: Biotechnology

   Key Executives:         CEO: Dr. Christophe Echeverri

   Public Relations
     Contact:              Ellen Fuerst
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 22, 2005
Words:131
Previous Article:Auto Club: Area Gas Prices Reach Plateau -- Slow Downward Trend Expected.
Next Article:Time to Get SEER-ious.



Related Articles
DANISH FIRMS MERGE TO FORM NORDIC BIOSCIENCE A/S.
LION GETS NEW AND UPGRADED LICENSES FOR SRS.
Research and Markets: Drug Discovery Market Based on RNAi Projected to be $1 billion by 2010.
ACADEMIC PILOT PROJECT INITIATES PUBLISHED STUDY.
Cenix BioScience and The Instituto de Medicina Molecular Initiate First Genome-Scale RNAi Screen for Novel Malaria Genes.
Cenix BioScience Delivers on Target Discovery Collaboration as Bayer HealthCare AG Acquires Potential Novel Therapeutic Targets Identified by RNAi...
Following Success of Pilot, Cenix BioScience and Schering AG Enter into Agreement on Multiple RNAi-Based Target Validation Projects.
Evaluate the Key & Niche Companies Operating in the World's Drug Discovery Technologies Industry.
Cenix BioScience and Merck KGaA Sign Framework Agreement for RNAi-Based Drug Discovery.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles